enteroviru
caus
handfootandmouth
diseas
well
neurolog
complic
young
children
interferon
ifn
inhibit
replic
mani
virus
low
cytotox
effect
previous
adenoviru
vector
mous
interferona
subtyp
gener
wu
et
al
studi
antivir
effect
evalu
murin
model
edayold
balbc
mice
administ
singl
dose
infect
lethal
dose
surviv
rate
clinic
symptom
tissu
viral
load
histolog
pathogenesi
evalu
ifn
gene
express
follow
singl
dose
maintain
high
concentr
pgml
day
mice
serum
preinfect
administr
singl
dose
pfu
offer
full
protect
mice
infect
compar
empti
vector
control
addit
viru
load
mice
muscl
tissu
significantli
decreas
compar
empti
vector
control
histopatholog
analysi
reveal
significantli
prevent
develop
sever
tissu
damag
reduct
viral
antigen
murin
muscl
tissu
postinfect
treatment
h
offer
full
protect
partial
protect
h
indic
could
use
therapeut
agent
earli
stage
infect
addit
studi
show
enhanc
neutral
abil
serum
mice
impli
could
promot
product
specif
antibodi
conclus
singl
dose
highli
efficaci
prophylact
agent
infect
vivo
enteroviru
caus
handfootandmouth
diseas
neurolog
complic
young
children
immunocompromis
adult
belong
enteroviru
genu
picornavirida
famili
nonenvelop
viru
singlestrand
positivesens
rna
genom
current
specif
drug
infect
five
inactiv
whole
viru
vaccin
current
develop
show
good
safeti
immunogen
clinic
trial
li
et
al
one
five
vaccin
approv
china
fda
recent
sinovac
obtain
new
drug
addit
formalininactiv
vaccin
phase
clinic
trial
show
strong
cross
neutral
abil
subgenotyp
coxsackieviru
chou
et
al
anoth
subgenotyp
vaccin
also
show
cross
neutral
abil
subgenotyp
zhu
et
al
subgenotyp
restrict
vaccin
compromis
vaccin
efficaci
limit
applic
clinic
type
interferon
group
broad
spectrum
antivir
cytokin
releas
host
cell
viral
infect
upon
bind
receptor
type
ifn
induc
hundr
downstream
gene
known
ifn
stimul
gene
isg
confer
antivir
state
host
cell
van
boxeldezair
et
al
specif
role
isg
host
antivir
respons
still
larg
unknown
among
isg
pkr
promot
apoptosi
virusinfect
cell
balachandran
et
al
takaoka
et
al
oligoadenyl
synthas
oa
activ
ifn
viral
infect
produc
oligoadenyl
activ
rnase
l
lead
degrad
viral
rna
stark
et
al
type
ifn
effect
inhibit
viral
infect
howev
applic
clinic
restrict
due
short
halflif
maintain
elev
serum
ifn
without
requir
repeat
inject
adenoviru
vector
interferona
name
gener
wu
et
al
interferon
speci
specif
mous
interferona
gene
construct
adenoviru
type
vector
control
strong
promot
p
cmv
upon
intranas
administr
adenoviru
vector
transduc
ifna
gene
nasal
epitheli
cell
ifna
express
constitut
vivo
studi
show
could
significantli
increas
halflif
ifna
protect
mice
virus
bacteria
infect
includ
western
equin
enceph
viru
wu
et
al
vaccinia
viru
smee
et
al
arenaviru
gowen
et
al
rift
valley
fever
viru
scharton
et
al
sar
coronaviru
kumaki
et
al
yellow
fever
viru
juland
et
al
chikungunya
viru
dagley
et
al
streptococcu
pneumonia
damjanov
et
al
date
antivir
effect
type
ifn
especi
vivo
effect
well
studi
previou
studi
show
poli
c
interferon
induc
significantli
protect
neonat
mice
lethal
challeng
liu
et
al
studi
effect
singl
dose
evalu
murin
model
rhabdomyosarcoma
cell
rd
use
quantif
plaqu
assay
human
embryo
kidney
cell
use
vector
prepar
enteroviru
strain
genbank
access
use
infect
mice
studi
use
test
antivir
efficaci
infect
empti
vector
use
test
control
stock
titer
pfuml
gener
use
method
describ
previous
wu
et
al
vector
prepar
plasmid
cut
paci
restrict
endonucleas
linear
plasmid
transfect
cell
lipofectamin
reagent
gener
vector
cultur
harvest
full
cpe
develop
vector
subsequ
propag
cell
vector
purifi
cesium
chlorid
ultracentrifug
use
method
describ
graham
et
al
vector
stock
use
studi
pfuml
viral
stock
vector
concentr
k
amicon
centrifug
filter
unit
prepar
pb
administr
mice
intranas
vitro
studi
cell
treat
differ
moi
cultur
fb
media
plate
h
posttreat
cell
cultur
supernat
collect
mifn
concentr
quantifi
elisa
r
system
cell
infect
vector
use
neg
control
vivo
studi
pfu
per
mous
administ
intranas
suckl
balbc
mice
dose
vector
control
blood
mice
collect
differ
time
point
day
posttreat
serum
separ
concentr
mous
interferona
serum
detect
elisa
r
system
administ
intranas
suckl
balbc
mice
dose
pfu
per
mous
bodi
weight
mice
weigh
daili
day
bodi
weight
loss
marker
cytotox
effect
chen
et
al
naiv
suckl
balbc
mice
use
neg
control
cytotox
studi
anim
work
perform
accord
iacucapprov
protocol
anim
biosafeti
level
facil
suckl
balbc
mice
purchas
invivo
mice
infect
enteroviru
day
old
g
bodi
weight
infect
uninfect
mice
fed
separ
cage
prevent
oralfec
transmiss
among
differ
group
mice
edayold
suckl
balbc
mice
infect
pfu
per
mous
virusinfect
mice
monitor
daili
day
postinfect
score
mice
clinic
score
system
supplementari
tabl
mice
clinic
score
system
use
score
sever
clinic
symptom
mice
score
system
involv
four
item
activ
diarrhea
movement
bodi
weight
chang
individu
mous
item
score
daili
sum
score
four
item
use
total
score
total
score
defin
endpoint
intranas
administ
nostril
mice
serial
dose
pfu
per
mous
prophylact
effect
administ
suckl
balbc
h
h
prior
challeng
mice
infect
pfu
per
mous
via
intraperiton
ip
inject
day
old
therapeut
effect
suckl
balbc
mice
infect
pfu
per
mous
day
old
intranas
administ
pfu
per
mous
h
h
postinfect
pfu
per
mous
empti
vector
use
treatment
control
upon
infect
surviv
mice
monitor
mice
score
system
mice
muscl
tissu
harvest
day
postinfect
dpi
viru
load
muscl
tissu
quantifi
plaqu
assay
histopatholog
studi
hind
limb
muscl
tissu
mice
harvest
dpi
fix
paraformaldehyd
week
c
decalcifi
room
temperatur
h
embed
paraffin
section
mm
thick
tissu
damag
evalu
haematoxylin
eosin
h
e
stain
antigen
detect
immunohistochemistri
stain
ihc
use
bondmax
system
antibodi
use
ihc
antibodi
dilut
mice
sacrif
day
postinfect
dpi
mice
tissu
includ
hind
limb
muscl
liver
spleen
brain
sera
collect
homogen
titrat
plaqu
form
assay
briefli
rd
cell
monolay
infect
mice
tissu
lysi
supernat
h
c
absorb
wash
twice
pb
overlaid
dmem
contain
fb
agaros
firstbas
monolay
incub
day
stain
crystal
violet
solut
contain
paraformaldehyd
prepar
fb
media
inactiv
uv
inactiv
confirm
plaqu
assay
mice
pretreat
pfu
vector
control
h
prior
challeng
mice
inject
pfu
uvinactiv
mice
serum
collect
day
postinject
incub
c
inactiv
complement
neutral
abil
mice
serum
evalu
neutral
assay
briefli
pfu
ml
dmem
media
mix
ml
serial
dilut
mice
serum
incub
c
h
incub
rd
cell
plate
infect
incub
mixtur
c
h
viru
absorpt
viru
mixtur
remov
rd
cell
wash
twice
pb
dmem
media
contain
agaros
ad
plate
plaqu
format
rd
cell
incub
day
stain
crystal
violet
solut
contain
paraformaldehyd
serum
mice
without
preinfect
treatment
inject
dmem
media
use
serum
control
plaqu
count
effect
neutral
determin
express
mifn
driven
shown
fig
transfect
cell
cultur
h
fig
show
robust
mifn
express
pgml
supernat
mifn
concentr
increas
multipl
infect
moi
depend
manner
minim
mifn
express
pgml
detect
upon
treatment
vector
control
express
mifn
stimul
evalu
vivo
fig
upon
intranas
treatment
dose
pfu
per
mous
abund
mifn
pgml
detect
mice
serum
day
postinfect
treatment
mifn
concentr
serum
vectortr
mice
within
rang
pgml
use
baselin
studi
day
postinfect
treatment
mifn
concentr
serum
mice
decreas
pgml
result
show
could
drive
robust
express
mifn
vitro
vivo
vivo
express
mifn
stimul
could
last
least
day
evalu
vivo
cytotox
effect
balbc
mice
intranas
administ
dose
pfu
per
mous
bodi
weight
mice
measur
daili
day
bodi
weight
chang
use
marker
cytotox
effect
chen
et
al
nontreat
naiv
mice
use
neg
control
cytotox
effect
shown
fig
suckl
mice
show
signific
bodi
weight
differ
compar
naiv
mice
clinic
symptom
includ
diarrhea
ruffl
fur
abnorm
movement
inact
observ
mice
togeth
result
show
minim
cytotox
effect
suckl
balbc
mice
balbc
mice
infect
via
intraperiton
inject
ip
titer
pfu
per
mous
prepar
dmem
media
contain
fb
mice
inject
volum
dmem
fb
media
use
mockinfect
control
mice
monitor
score
daili
use
score
system
mention
shown
fig
mortal
observ
day
postinfect
dpi
h
interferona
concentr
cultur
supernat
detect
elisa
b
balbc
mice
treat
intranas
pfu
per
mous
serum
ifna
concentr
quantifi
differ
time
point
elisa
empti
vector
use
control
vitro
vivo
studi
vitro
data
present
mean
standard
deviat
three
biolog
repeat
vivo
data
present
mean
individu
valu
five
mice
p
pair
ttest
compar
vector
control
bodi
weight
chang
measur
cytotox
effect
suckl
balbc
mice
balbc
mice
treat
intranas
pfu
naiv
mice
use
control
bodi
weight
use
marker
cytotox
effect
bodi
weight
mice
measur
daili
day
compar
untreat
control
data
present
bodi
weight
mean
standard
deviat
six
mice
mice
mice
develop
sever
clinic
symptom
includ
inact
loss
bodi
weight
ruffl
fur
hind
limb
paralysi
fig
show
high
clinic
score
mice
compar
mock
control
show
minim
clinic
symptom
detect
viral
load
mice
tissu
liver
spleen
brain
sera
hind
limb
muscl
harvest
dpi
viral
load
quantifi
plaqu
assay
viral
load
detect
hind
limb
muscl
tissu
pfu
per
gram
viru
detect
spleen
liver
brain
sera
fig
balbc
mice
model
balbc
mice
infect
pfu
per
mous
fb
use
mockinfect
control
surviv
mice
monitor
daili
day
clinic
score
system
b
clinic
symptom
mice
includ
bodi
weight
chang
activ
diarrhea
movement
score
daili
day
accord
sever
symptom
c
viral
load
mice
tissu
includ
hind
limb
muscl
blood
spleen
liver
brain
tissu
detect
day
postinfect
plaqu
assay
group
contain
mice
surviv
curv
gener
signific
calcul
graphpad
softwar
clinic
score
present
mean
standard
deviat
viral
load
five
mice
present
mean
individu
valu
tissu
damag
viral
antigen
hind
limb
muscl
tissu
mice
detect
day
postinfect
muscl
tissu
damag
mice
detect
h
e
stain
e
muscl
tissu
mice
inject
fb
media
use
mock
control
f
viral
antigen
muscl
infect
mice
detect
immunohistochemistri
stain
ihc
use
bondmax
system
g
muscl
tissu
fb
mediainject
mice
control
antibodi
use
ihc
dilut
confirm
presenc
hind
limb
muscl
tissu
haematoxylin
eosin
h
e
stain
perform
detect
tissu
damag
immunohistochemistri
ihc
stain
perform
detect
viral
antigen
fig
h
e
stain
reveal
dpi
caus
sever
tissu
damag
hind
limb
muscl
tissu
indic
destruct
muscl
fiber
massiv
cell
infiltr
also
observ
suggest
infect
caus
sever
inflamm
hind
limb
muscl
tissu
report
infect
immun
cell
mainli
neutrophil
macrophag
recruit
infect
site
releas
abund
proinflammatori
cytokin
led
tissu
damag
wang
et
al
ihc
studi
reveal
abund
viral
antigen
present
hind
limb
muscl
tissu
infect
mice
fig
compar
mockinfect
mice
fig
indic
establish
signific
infect
hind
limb
muscl
tissu
mice
dosedepend
prophylact
effect
suckl
balbc
mice
evalu
prophylact
effect
balbc
suckl
mice
intranas
administ
differ
dose
pfu
per
mous
h
prior
infect
empti
vector
given
similar
dose
treatment
control
balbc
suckl
mice
infect
day
old
monitor
day
clinic
score
system
mention
supplementari
tabl
shown
fig
pfu
pfu
offer
full
protect
mice
lethal
challeng
compar
vector
pbstreat
control
show
protect
effect
low
dose
pfu
show
death
rate
indic
pfu
effect
protect
mice
infect
fig
show
clinic
score
group
mice
consist
surviv
rate
clinic
symptom
score
decreas
dosedepend
manner
vectoror
pbstreat
mice
develop
sever
infect
symptom
signific
clinic
score
vector
antivir
effect
compar
pb
indic
antivir
effect
mainli
due
express
mifn
fig
show
infecti
viral
load
muscl
tissu
compar
empti
vector
administ
control
significantli
decreas
infecti
viral
load
hind
limb
muscl
tissu
dosedepend
manner
consist
clinic
score
mice
also
decreas
dosedepend
manner
confirm
prophylact
effect
h
e
stain
perform
mice
administ
h
challeng
compar
fig
doserespons
surviv
curv
clinic
score
viral
load
detect
upon
intranas
administr
murin
model
suckl
balbc
mice
dose
prior
challeng
differ
level
pfu
per
mous
infect
pfu
per
mous
prepar
pb
empti
vector
pb
use
treatment
control
surviv
mice
monitor
daili
week
mice
score
system
b
clinic
symptom
score
c
viru
load
hind
limb
muscl
tissu
detect
plaqu
assay
group
contain
mice
surviv
curv
gener
signific
calcul
graphpad
softwar
clinic
score
present
mean
clinic
score
viral
load
present
mean
individu
valu
empti
control
mice
develop
massiv
loss
muscl
fiber
tissu
damag
observ
upon
preinfect
administr
pfu
higher
dose
suggest
complet
inhibit
muscl
tissu
damag
caus
infect
fig
consist
inhibit
tissu
damag
immun
cell
infiltr
detect
muscl
tissu
mice
pfu
suggest
inhibit
tissu
inflamm
induc
infect
detect
whether
could
inhibit
replic
mice
muscl
tissu
ihc
perform
fig
consist
viru
load
detect
administr
h
fig
prophylact
effect
measur
surviv
curv
clinic
score
viral
load
detect
upon
prechalleng
administr
murin
model
suckl
balbc
mice
dose
h
prior
challeng
pfu
per
mous
infect
pfu
per
mous
vector
use
treatment
control
surviv
mice
monitor
day
use
clinic
score
system
b
clinic
symptom
score
c
viru
load
muscl
tissu
detect
plaqu
assay
group
contain
mice
surviv
curv
gener
signific
calcul
graphpad
softwar
clinic
score
present
mean
standard
deviat
clinic
score
mice
viral
load
five
mice
present
mean
individu
valu
tissu
damag
viral
antigen
muscl
tissu
detect
day
postinfect
muscl
tissu
damag
mice
detect
h
e
stain
e
muscl
tissu
mice
treat
vector
use
control
f
viral
antigen
muscl
tissu
mice
detect
ihc
use
bondmax
system
antibodi
dilut
g
vector
use
treatment
control
prior
challeng
viral
antigen
significantli
reduc
muscl
tissu
mice
indic
could
potent
inhibit
replic
muscl
tissu
mice
shown
fig
mifn
stimul
could
last
day
mice
serum
therefor
antivir
effect
might
abl
last
week
one
group
mice
administ
h
prior
challeng
dose
pfu
per
mous
full
protect
well
minim
clinic
score
observ
fig
addit
administr
h
prechalleng
viru
load
muscl
tissu
mice
significantli
decreas
fig
furthermor
administr
h
prechalleng
protect
mice
tissu
damag
inhibit
replic
muscl
tissu
fig
data
clearli
indic
prechalleng
dose
prophylact
effect
mice
howev
worth
note
longterm
prophylact
effect
could
determin
murin
model
due
age
limit
suckl
mice
evalu
therapeut
effect
balbc
suckl
mice
infect
h
h
postinfect
mice
intranas
dose
pfu
per
mous
dose
empti
vector
use
treatment
control
shown
fig
full
protect
minim
clinic
symptom
observ
h
postinfect
treatment
compar
vector
show
protect
h
postinfect
treatment
delay
death
surviv
rate
observ
murin
model
studi
show
postinfect
treatment
significantli
decreas
viru
load
mice
muscl
tissu
fig
howev
consist
surviv
studi
histopatholog
analysi
reveal
reduc
antigen
muscl
tissu
prevent
mice
develop
sever
tissu
damag
inflamm
fig
result
strongli
demonstr
therapeut
effect
inhibit
tissu
damag
viral
replic
muscl
tissu
earli
stage
infect
fig
treatment
effect
measur
surviv
curv
clinic
score
viral
load
detect
upon
postinfect
treatment
murin
model
suckl
balbc
mice
infect
pfu
per
mous
treat
pfu
per
mous
h
h
postinfect
dose
vector
use
treatment
control
surviv
mice
monitor
daili
week
mice
score
system
b
clinic
symptom
score
c
viru
load
muscl
tissu
detect
plaqu
assay
group
contain
mice
surviv
curv
gener
signific
calcul
graphpad
softwar
clinic
score
present
mean
standard
deviat
clinic
score
mice
viral
load
five
mice
present
mean
individu
valu
tissu
damag
viral
antigen
muscl
tissu
mice
detect
day
postinfect
tissu
damag
detect
h
e
stain
h
f
h
postinfect
treatment
compar
e
g
vector
control
consist
tissu
damag
detect
significantli
decreas
viral
antigen
shown
ihc
mice
h
h
j
h
postinfect
treatment
compar
k
vector
control
use
ihc
dilut
ifn
mainli
involv
innat
immun
system
directli
inhibit
replic
virus
howev
previou
studi
report
ifn
also
play
role
acquir
immun
system
ifn
could
enhanc
antibodi
product
enhanc
b
cell
develop
differenti
neubauer
et
al
jego
et
al
ifn
also
promot
immunoglobulin
class
switch
igm
igg
enhanc
specif
antibodi
finkelman
et
al
long
term
antibodi
product
immun
memori
also
induc
ifn
le
et
al
thu
might
abl
enhanc
neutral
abil
antibodi
mice
serum
infect
evalu
balbc
suckl
mice
intranas
dose
pfu
per
mous
h
prior
challeng
empti
vector
control
mice
vaccin
uvinactiv
nonrepl
pfu
per
mous
via
ip
inject
mice
serum
collect
differ
time
point
postvaccin
neutral
abil
mice
serum
evalu
neutral
assay
shown
fig
comparison
vector
control
serum
mice
given
show
higher
neutral
abil
day
postinject
uvinactiv
statist
studi
show
percentag
neutral
mice
serum
significantli
lower
upon
treatment
comparison
control
fig
result
support
could
enhanc
product
specif
neutral
antibodi
vivo
studi
shown
first
time
singl
dose
highli
efficaci
prophylact
agent
dosedepend
manner
infect
vivo
murin
model
pfu
offer
full
protect
mice
lethal
infect
therapeut
applic
offer
protect
mice
earli
stage
infect
less
h
indic
limit
effect
late
stage
mous
infect
symptom
alreadi
develop
clinic
latenc
infect
sever
day
limit
antivir
effect
suggest
applic
treatment
infect
restrict
howev
one
import
point
murin
model
lethal
dose
viru
use
quickli
establish
signific
infect
mice
tissu
led
death
mice
clinic
infect
usual
selflimit
diseas
mild
symptom
featur
hand
foot
mouth
symptom
thu
still
chanc
might
effect
treat
infect
patient
develop
symptom
diseas
progress
less
sever
evalu
clinic
therapeut
efficaci
infect
studi
necessari
addit
antivir
effect
ifn
also
play
role
regul
immun
cell
develop
b
cell
previou
studi
shown
ifn
import
b
cell
activ
antibodi
product
antibodi
class
switch
le
et
al
studi
shown
abl
enhanc
product
neutral
antibodi
thu
use
broadspectrum
immun
stimul
agent
prevent
viral
infect
well
infecti
diseas
furthermor
might
use
adjuv
enhanc
product
antibodi
efficaci
vaccin
addit
virus
report
inhibit
previous
report
preinfect
dose
pfu
could
offer
protect
mice
differ
strain
western
equin
enceph
viru
weev
includ
highlyvirul
strain
fig
neutral
assay
serum
mice
mice
dose
pfu
vector
control
h
prior
challeng
inject
pfu
uvinactiv
day
old
mice
serum
collect
day
postinject
incub
c
inactiv
complement
neutral
abil
mice
serum
evalu
neutral
assay
serum
mice
show
enhanc
neutral
abil
compar
vector
control
day
b
day
c
day
postinject
percentag
nonneutr
virus
upon
incub
mice
serum
calcul
graphpad
accord
neutral
curv
data
present
mean
standard
deviat
signific
calcul
ttest
p
fleme
wu
et
al
postinfect
treatment
h
post
weev
infect
also
protect
similar
inhibit
pattern
also
observ
vaccinia
viru
smee
et
al
arenaviru
gowen
et
al
sar
coronaviru
kumaki
et
al
yellow
fever
viru
juland
et
al
chikungunya
viru
dagley
et
al
preinfect
treatment
pfu
offer
signific
protect
vivo
dosedepend
manner
postinfect
treatment
earli
timepoint
post
infect
effect
togeth
result
demonstr
preinfect
treatment
abl
inhibit
infect
varieti
virus
use
broadspectrum
antivir
agent
use
adenoviru
vector
vivo
constitut
ifn
express
platform
evalu
serum
ifn
induc
long
term
antivir
effect
singl
dose
studi
show
ifn
produc
pfu
maintain
high
level
least
day
mice
serum
demonstr
effect
halflif
ifn
significantli
prolong
continu
releas
ifn
bloodstream
illustr
whether
long
term
antivir
effect
test
antivir
effect
h
preinfect
treatment
murin
model
due
age
limit
suckl
mice
model
abl
show
preinfect
treatment
effect
least
h
infect
howev
previou
studi
shown
antivir
effect
could
last
least
week
weev
day
vaccinia
viru
might
due
three
reason
firstli
antivir
state
host
cell
last
long
term
upon
ifn
stimul
secondli
ifn
continu
produc
transduc
cell
thirdli
immun
system
stimul
offer
long
term
antivir
protect
conclus
result
demonstr
abl
offer
long
term
antivir
protect
vivo
howev
robust
last
express
ifn
induc
might
caus
ifnrel
side
effect
headach
diarrhea
nausea
although
observ
side
effect
suckl
mice
differ
anim
model
clinic
applic
consid
thu
clinic
evalu
side
effect
necessari
especi
children
sinc
vulner
hfmd
addit
use
adenoviru
vector
might
stimul
immun
respons
vector
might
lead
inflamm
inocul
site
especi
peopl
preexist
immun
respons
adenoviru
though
inocul
via
intranas
administr
minim
exposur
adenoviru
vector
immun
system
thu
immun
respons
evalu
clinic
trial
one
approach
avoid
immun
respons
peopl
preexist
immun
respons
adenoviru
chang
anoth
deliveri
vector
addit
ifn
subtyp
mous
howev
inhibit
previou
studi
show
effect
type
ifn
although
type
ifn
inhibit
effect
yi
et
al
thu
human
version
consid
treatment
infect
conclus
shown
singl
dose
highli
efficaci
prophylact
agent
infect
vivo
furthermor
significantli
enhanc
neutral
abil
antibodi
mice
serum
clinic
prophylact
effect
worth
evalu
